Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Adenocarcinoma
Disparities seen in cervical cancer incidence, screening
By
LabPulse.com staff writers
But white women have seen a greater annual increase in cervical cancer rates, particularly in adenocarcinomas, noted a team led by Dr. Alex Francoeur from the University of California, Los Angeles. The researchers found that white women have lower rates of guideline screening and vaccination compared with Black women.
August 18, 2022
Immunovia applies to AMA for PLA code
By
LabPulse.com staff writers
The company has touted the results of a study showing that the test detected stage I/II pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity.
April 17, 2022
Immunovia touts performance of PanCan-d test in clinical study
By
LabPulse.com staff writers
The test detected pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity in stage I/II when excluding individuals with low levels of CA 19-9, an antigen released by pancreatic cancer cells.
February 17, 2022
Universal Diagnostics touts blood-based lung cancer test
By
LabPulse.com staff writers
Presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference, the test uses methylation status measurement of the tumor-derived portion from cell-free DNA (cfDNA) in plasma for patient classification. Researchers examined plasma samples of 37 lung cancer patients and 71 asymptomatic age, gender, and smoking-history matching controls.
January 28, 2021
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
By
LabPulse.com staff writers
The partnership is designed to improve treatment response and survival rates of patients with pancreatic ductal adenocarcinoma (PDAC) tumors. It will utilize PanCan's patient molecular and outcomes data and GeneCentric's RNA-based portfolio, which includes the PurlSt profiler that identifies PDAC subtypes.
July 30, 2020
Google reports pathology AI helps predict survival in cancer patients
By
Emily Hayes
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
How to manage genetic testing of pancreatic cancer patients
By
Emily Hayes
The National Comprehensive Cancer Network recently recommended germline testing for all people newly diagnosed with pancreatic ductal adenocarcinoma (PDAC). Also, the American Society of Clinical Oncology has issued a clinical opinion advising risk assessment and consideration of germline testing for all patients newly diagnosed, Dr. Eileen O'Reilly, an oncologist at Memorial Sloan Kettering Cancer Center, and colleagues observed. But opinions on what, exactly, to test for have been divided, and guidance has been lacking, they suggested in JAMA Oncology.
February 13, 2020
NCCN updates pathology guidance in ovarian cancer
By
LabPulse.com staff writers
In the new version, released on November 26, the guidelines now read:
December 1, 2019
Page 1 of 1